Join us for an expert-led webinar, sponsored by AstraZeneca and Daiichi Sankyo, on navigating the metastatic breast cancer treatment landscape, with a focus on optimising patient care with Enhertu (trastuzumab deruxtecan) for HER2-positive and HER2-low metastatic breast cancer. This session will explore the latest evidence, practical considerations, and real-world applications of Enhertu in clinical practice, equipping you with the knowledge and expertise to contribute to improved patient outcomes.
This webinar will provide practical insights into:
-
Patient selection and eligibility for Enhertu
-
Managing toxicities and treatment-related considerations
-
Optimising supportive care for patients on Enhertu
-
Real-world case discussion
CNSA is grateful to Daiichi Sankyo and Astra Zeneca for sponsoring this educational event.